OUCHIE !!!

Bob ‘n Weave Blaskiewicz selected from his
select “Sexual Predator” syllabus he must cite from; during sessions like his series at the University of Wisconsin-Eau Claire, where he surely must supply sorry examples of how to supposedly elicit a “Pavlov’s dog” style series of events from confused children; who’ve been told to “not talk to strangers,” and “never go anywhere with someone you don’t know,” when he Gabroni’s this gem and juice:
——————————————————————
“He IS big pharma” [1]
——————————————————————
How quaint

Bob is unable to back-up his biased talking-head brillnuance

But he hopes mightily that his brilliance of adding the nut menagerie symbolism of menutgerie:
——————————————————————
“He uses the same legal loopholes available to drug companies … “ [2]
——————————————————————
Basically, “The Skeptics™,” according to Bob, believe that every law they disagree with is a “legal loophole,” but every law they might not agree with, but which their opposition feels is a “legal loophole,” is a valid law to them

But I digress

Bob would have you believe that he thinks his readers are NOT smarter than a fifth-grader; and perhaps that belief is well founded, because a lot of Bob’s regular followers may not really be: smarter than a 5tłh-grader”, based on his theory that if a child were instructed to never go somewhere with a stranger, Bob believes that children, like his readers, can be “suckered” into ignoring warnings, and instead, if they are told a “plausible story” like:
——————————————————————
“Your parent needs your help and they want you to follow me”

“They have some candy for you”
——————————————————————
they will forego that which they have been told is the intelligent, correct choice, for the big, shiny, fruit of the stupid stick tree
——————————————————————
Now, let’s review Blatherskitewicz’s attempt at Tolstory:
——————————————————————
“He IS big pharma”: “He uses the same legal loopholes available to drug companies … “
——————————————————————
A 5th-grader is smart enough to see through Bobby’s piss-poor Pulitzer Prize phallicy

Bobby excreted end-run attempt around intelligent-design, is his word-salad salute to
“Stupid is, as Stupid Does”

He tries to MisDisInform, by depositing that because Burzynski has to use the same, as he puts it, “legal loopholes” as BILLION Pharma, that this somehow translates into Burzynski being Big Pharma

Jeepers, creepers, this would be akin to me attempting to pull a Pol Pot over your Peepers, by trying to claim that just because Bobby Blatherskitewicz sits down and uses the same type of device; a toilet, to attempt to rid himself of what he is obviously “full of,” that this means he is smarter than a 5th-grader who uses the same device, when it is clear that even medical-grade cannabis couldn’t help Bobby Blatherskite be smarter than a 5th-grader
——————————————————————
“He IS big pharma”: “He uses the same large poophole“, and even the largest roll of Charmin in the world wouldn’t help him
——————————————————————
Since Booby couldn’t name an actual Big pharmaceutical company to contrast Burzynski with, let’s take a look at one, shall we ?
——————————————————————
2/7/2012, Monday, GlaxoSmithKline LLC (GSK) was fined $3 BILLION ($3,000,000,000 Billion) dollars, for actions which occurred from
(4/1998 – 2007)

How did this $3 BILLION dollar slap on the wrist affect GSK ?
——————————————————————
Well, I’m glad you asked !
——————————————————————
Before “Black Monday”, 2/7/2012, EARNINGS PER SHARE was:

40.6¢ – .12/31/2011 (3 months ended)

Afterwards, a 1.6¢ rise:

42.2¢ – 3/31/2012 (3 months ended)
——————————————————————
Before the United States Department of Justice’s devastating news, Profit attributable to shareholders was:

$2,017,000,000 BILLION – .12/31/2011 (3 months ended)

After, a $77 MILLION ($77,000,000 Million) dollar rise to:

$2,094,000,000 BILLION – 3/31/2012 (3 months ended)
——————————————————————
Before the 2/7/2012 surprise, Cash and cash equivalents (Current assets) was:

$8,857,000,000 BILLION – .12/31/2011 (3 months ended)

Afterward, a $161 MILLION ($161,000,000 Million) rise to:

$9,018,000,000 BILLION – 3/31/2012 (3 months ended)
——————————————————————
Before the announcement, Total current assets:

$25,059,000,000 BILLION – .12/31/2011 (3 months ended)

After the FALL, a $986 MILLION ($986,000,000 Million RISE to:

$26,045,000,000 BILLION – 3/31/2012 (3 months ended)
——————————————————————
And, last, but certainly NOT in any way, shape, or form, least, before “that” day, TOTAL ASSETS

$63,674,000,000 BILLION – .12/31/2011 (3 months ended)

The aftermath, a $1,610 BILLION ($1,610,000,000 Billion) increase to:

$65,284,000,000 BILLION – 3/31/2012 (3 months ended)
——————————————————————
With the current TOTAL ASSETS being a miserly:

$66,598,000,000 BILLION – 9/30/2013 (3 months ended)
——————————————————————
I’m NOT quite sure how they’ll be able to function!!
======================================
Next, Bob Blaskiewicz tries to claim that since his vehicle uses gas, and a Rolls Royce uses gas, his car is like a Rolls Royce Silver Arrow
——————————————————————
.12/31/2011 (3 months ended) Cash and cash equivalents (Current assets)
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
33.871514056678336%
of
$8,857,000,000 BILLION
——————————————————————
2/7/2012 – $3 BILLION ($3,000,000,000 fine)
——————————————————————
3/31/2012 (3 months ended) Cash and cash equivalents (Current assets)
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
33.2667997338656%
of
$9,018,000,000 BILLION
——————————————————————
.12/31/2011 (3 months ended) Total current assets
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
11.971746677840295%
of
$25,059,000,000 BILLION
——————————————————————
2/7/2012 – $3 BILLION ($3,000,000,000 fine)
——————————————————————
3/31/2012 (3 months ended) Total current assets
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
11.518525628719523%
of
$26,045,000,000 BILLION
——————————————————————
.12/31/2011 (3 months ended) TOTAL ASSETS
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
4.711499199045136%
of
$63,674,000,000 BILLION
——————————————————————
2/7/2012 – $3 BILLION ($3,000,000,000 fine)
——————————————————————
3/31/2012 (3 months ended) TOTAL ASSETS
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
4.5953066601311185%
of
$65,284,000,000 BILLION
——————————————————————
9/30/2013 (3 months ended) current TOTAL ASSETS
——————————————————————
$3 BILLION (3,000,000,000 Billion)
is
4.504639778972342%
of
$66,598,000,000 BILLION
——————————————————————
Gross Domestic Product (GDP)
——————————————————————
67 countries
68th – GSK would rank ($66,598,000,000 BILLION)
of
214
——————————————————————
======================================
EARNINGS PER SHARE
——————————————————————
95.2¢☝9/30/2013 (9 months ended)
31.0¢👇9/30/2013 (3 months ended)
64.2¢☝6/30/2013 (6 months ended)
33.1¢☝6/30/2013 (3 months ended
31.0¢👇3/31/2013 (3 months ended)
$147.7☝.12/31/2012 (12 months ended)
28.8¢👇.12/31/2012 (3 months ended)
$118.5☝9/30/2012 (9 months ended)
36.2¢👇9/30/2012 (3 months ended)
82.3¢☝6/30/2012 (6 months ended)
40.1¢☝6/30/2012 (3 months ended)
42.2¢👇3/31/2012 (3 months ended)
$168.4☝.12/31/2011 (12 months ended)
40.6¢👇.12/31/2011 (3 months ended)
$127.8☝9/30/2011 (9 months ended)
43.9¢👇9/30/2011 (3 months ended)
83.9¢☝6/30/2011 (6 months ended)
35.8¢👇6/30/2011 (3 months ended)
48.0¢👇3/31/2011 (3 months ended)
49.8¢☝.12/31/2010 (12 months ended)
(–21.5¢ LOSS)👇.12/31/2010 (3 months ended)
70.4¢☝9/30/2010 (9 months ended)
39.5¢☝9/30/2010 (3 months ended)
31.2¢☝6/30/2010 (6 months ended)
(– 9.0¢ LOSS)👇6/30/2010 (3 months ended)
41.2¢👇3/31/2010 (3 months ended)
$170.2☝.12/31/2009 (12 months ended)
52.0¢👇.12/31/2009 (3 months ended)
$118.6 ☝9/30/2009 (9 months ended)
42.6¢👇9/30/2009 (3 months ended)
75.9¢☝6/30/2009 (6 months ended)
44.1¢☝6/30/2009 (3 months ended)
32.1¢☝3/31/2009 (3 months ended)
——————————————————————
12 months ended (12/31/2009-12/31/2012)
——————————————————————
$147.7👇.12/31/2012 (12 months ended)
$168.4☝.12/31/2011 (12 months ended)
49.8¢👇.12/31/2010 (12 months ended)
$170.2☝.12/31/2009 (12 months ended)
——————————————————————
9 months ended (9/30/2009-9/30/2013)
——————————————————————
95.2¢👇9/30/2013 (9 months ended)
$118.5👇9/30/2012 (9 months ended)
$127.8☝9/30/2011 (9 months ended)
70.4¢👇9/30/2010 (9 months ended)
$118.6☝9/30/2009 (9 months ended)
——————————————————————
6 months ended (6/30/2009-6/30/2013)
——————————————————————
64.2¢👇6/30/2013 (6 months ended)
82.3¢👇6/30/2012 (6 months ended)
83.9¢☝6/30/2011 (6 months ended)
31.2¢👇6/30/2010 (6 months ended)
75.9¢☝6/30/2009 (6 months ended)
——————————————————————
3 months ended (3/31/2009-9/30/2013)
——————————————————————
31.0¢👇9/30/2013 (3 months ended)
33.1¢☝6/30/2013 (3 months ended)
31.0¢☝3/31/2013 (3 months ended)
28.8¢👇.12/31/2012 (3 months ended)
36.2¢👇9/30/2012 (3 months ended)
40.1¢👇6/30/2012 (3 months ended)
42.2¢☝3/31/2012 (3 months ended)
40.6¢👇.12/31/2011 (3 months ended)
43.9¢☝9/30/2011 (3 months ended)
35.8¢👇6/30/2011 (3 months ended)
48.0¢☝3/31/2011 (3 months ended)
(– 21.5¢ LOSS)👇.12/31/2010 (3 months ended)
39.5¢☝9/30/2010 – (3 months ended)
(– 9.0¢ LOSS)👇6/30/2010 (3 months ended)
41.2¢👇3/31/2010 (3 months ended)
52.0¢☝.12/31/2009 (3 months ended)
42.6¢👇9/30/2009 (3 months ended)
44.1¢☝6/30/2009 (3 months ended)
32.1¢☝3/31/2009 (3 months ended)
——————————————————————
Profit attributable to shareholders
——————————————————————
$4,611,000,000 BILLION☝9/30/2013 (9 months ended)
$1,502,000,000 BILLION👇9/30/2013 (3 months ended)
$3,109,000,000 BILLION☝6/30/2013 (6 months ended)
$1,610,000,000 BILLION☝6/30/2013 (3 months ended)
$1,499,000,000 BILLION👇3/31/2013 (3 months ended)
$7,258,000,000 BILLION☝.12/31/2012 (12 months ended)
$1,410,000,000 BILLION👇.12/31/2012 (3 months ended)
$5,848,000,000 BILLION☝9/30/2012 (9 months ended)
$1,773,000,000 BILLION👇9/30/2012 (3 months ended)
$4,075,000,000 BILLION☝6/30/2012 (6 months ended)
$1,981,000,000 BILLION👇6/30/2012 (3 months ended)
$2,094,000,000 BILLION👇3/31/2012 (3 months ended)
$8,471,000,000 BILLION☝.12/31/2011 (12 months ended)
$2,017,000,000 BILLION👇.12/31/2011 (3 months ended)
$6,454,000,000 BILLION☝9/30/2011 (9 months ended)
$2,191,000,000 BILLION👇9/30/2011 (3 months ended)
$4,263,000,000 BILLION☝6/30/2011 (6 months ended)
$1,824,000,000 BILLION👇6/30/2011 (3 months ended)
$2,439,000,000 BILLION👇3/31/2011 (3 months ended)
$2,532,000,000 BILLION☝.12/31/2010 (12 months ended)
(–$1,046,000,000 BILLION LOSS)👇.12/31/2010 (3 months ended)
$3,578,000,000 BILLION☝9/30/2010 (9 months ended)
$1,993,000,000 BILLION☝9/30/2010 – (3 months ended)
$1,585,000,000 BILLION☝6/30/2010 (6 months ended)
(– $505,000,000 million LOSS)👇6/30/2010 (3 months ended)
$2,090,000,000 BILLION👇3/31/2010 (3 months ended)
$8,629,000,000 BILLION☝.12/31/2009 (12 months ended)
$2,622,000,000 BILLION👇.12/31/2009 (3 months ended)
$6,007,000,000 BILLION☝9/30/2009 (9 months ended)
$2,158,000,000 BILLION👇9/30/2009 (3 months ended)
$3,849,000,000 BILLION👇6/30/2009 (6 months ended)
$3,849,000,000 BILLION☝6/30/2009 (3 months ended)
$1,629,000,000 BILLION☝3/31/2009 (3 months ended)
——————————————————————
12 months ended (12/31/2009-12/31/2012)
——————————————————————
$7,258,000,000 BILLION👇.12/31/2012 (12 months ended)
$8,471,000,000 BILLION☝.12/31/2011 (12 months ended)
$2,532,000,000 BILLION👇.12/31/2010 (12 months ended)
$8,629,000,000 BILLION☝.12/31/2009 (12 months ended)
——————————————————————
9 months ended (9/30/2009-9/30/2013
——————————————————————
$4,611,000,000 BILLION👇9/30/2013 (9 months ended)
$5,848,000,000 BILLION👇9/30/2012 (9 months ended)
$6,454,000,000 BILLION☝9/30/2011 (9 months ended)
$3,578,000,000 BILLION👇9/30/2010 (9 months ended)
$6,007,000,000 BILLION☝9/30/2009 (9 months ended)
——————————————————————
6 months ended (6/30/2009-6/30/2013)
——————————————————————
$3,109,000,000 BILLION👇6/30/2013 (6 months ended)
$4,075,000,000 BILLION👇6/30/2012 (6 months ended)
$4,263,000,000 BILLION☝6/30/2011 (6 months ended)
$1,585,000,000 BILLION👇6/30/2010 (6 months ended)
$3,849,000,000 BILLION☝6/30/2009 (6 months ended)
——————————————————————
3 months ended (3/31/2009-9/30/2013)
——————————————————————
$1,502,000,000 BILLION👇9/30/2013 (3 months ended)
$1,610,000,000 BILLION☝6/30/2013 (3 months ended)
$1,499,000,000 BILLION☝3/31/2013 (3 months ended)
$1,410,000,000 BILLION👇.12/31/2012 (3 months ended)
$1,773,000,000 BILLION👇9/30/2012 (3 months ended)
$1,981,000,000 BILLION👇6/30/2012 (3 months ended)
$2,094,000,000 BILLION☝3/31/2012 (3 months ended)
$2,017,000,000 BILLION👇.12/31/2011 (3 months ended)
$2,191,000,000 BILLION☝9/30/2011 (3 months ended)
$1,824,000,000 BILLION👇6/30/2011 (3 months ended)
$2,439,000,000 BILLION☝3/31/2011 (3 months ended)
(– $1,046,000,000 BILLION LOSS)👇.12/31/2010 (3 months ended)
$1,993,000,000 BILLION☝9/30/2010 – (3 months ended)
(– $505,000,000 million LOSS)👇6/30/2010 (3 months ended)
$2,090,000,000 BILLION👇3/31/2010 (3 months ended)
$2,622,000,000 BILLION☝.12/31/2009 (3 months ended)
$2,158,000,000 BILLION👇9/30/2009 (3 months ended)
$3,849,000,000 BILLION☝6/30/2009 (3 months ended)
$1,629,000,000 BILLION☝3/31/2009 (3 months ended)
——————————————————————
Cash and cash equivalents (Current assets)
——————————————————————
$5,268,000,000 BILLION☝9/30/2013 (3 months ended)
$4,318,000,000 BILLION👇6/30/2013 (3 months ended)
$5,825,000,000 BILLION👇3/31/2013 (3 months ended)
$6,820,000,000 BILLION☝.12/31/2012 (3 months ended)
$5,459,000,000 BILLION👇9/30/2012 (3 months ended)
$11,601,000,000 BILLION☝6/30/2012 (3 months ended)
$9,018,000,000 BILLION☝3/31/2012 (3 months ended)
$8,857,000,000 BILLION☝.12/31/2011 (3 months ended)
$8,446,000,000 BILLION👇9/30/2011 (3 months ended)
$9,412,000,000 BILLION👇6/30/2011 (3 months ended)
$10,397,000,000 BILLION☝3/31/2011 (3 months ended)
$9,449,000,000 BILLION👇.12/31/2010 (3 months ended)
$9,842,000,000 BILLION👇9/30/2010 – (3 months ended)
$9,861,000,000 BILLION👇6/30/2010 (3 months ended)
$10,585,000,000 BILLION☝3/31/2010 (3 months ended)
$10,357,000,000 BILLION☝.12/31/2009 (3 months ended)
$10,347,000,000 BILLION☝9/30/2009 (3 months ended)
$8,821,000,000 BILLION👇6/30/2009 (3 months ended)
$8,896,000,000 BILLION☝3/31/2009 (3 months ended)
——————————————————————
Total current assets
——————————————————————
$21,825,000,000 BILLION☝9/30/2013 (3 months ended)
$20,423,000,000 BILLION👇6/30/2013 (3 months ended)
$21,458,000,000 BILLION👇3/31/2013 (3 months ended)
$22,318,000,000 BILLION☝.12/31/2012 (3 months ended)
$21,724,000,000 BILLION👇9/30/2012 (3 months ended)
$27,105,000,000 BILLION☝6/30/2012 (3 months ended)
$26,045,000,000 BILLION☝3/31/2012 (3 months ended)
$25,059,000,000 BILLION👇.12/31/2011 (3 months ended)
$25,573,000,000 BILLION👇9/30/2011 (3 months ended)
$26,257,000,000 BILLION👇6/30/2011 (3 months ended)
$26,882,000,000 BILLION☝3/31/2011 (3 months ended)
$25,016,000,000 BILLION👇.12/31/2010 (3 months ended)
$26,533,000,000 BILLION☝9/30/2010 – (3 months ended)
$25,619,000,000 BILLION👇6/30/2010 (3 months ended)
$27,901,000,000 BILLION👇3/31/2010 (3 months ended)
$28,288,000,000 BILLION☝.12/31/2009 (3 months ended)
$27,745,000,000 BILLION☝9/30/2009 (3 months ended)
$25,161,000,000 BILLION☝6/30/2009 (3 months ended)
$24,263,000,000 BILLION☝3/31/2009 (3 months ended)
——————————————————————
TOTAL ASSETS
——————————————————————
$66,598,000,000 BILLION☝9/30/2013 (3 months ended)
$63,930,000,000 BILLION👇6/30/2013 (3 months ended)
$65,196,000,000 BILLION👇3/31/2013 (3 months ended)
$67,604,000,000 BILLION☝.12/31/2012 (3 months ended)
$65,129,000,000 BILLION👇9/30/2012 (3 months ended)
$66,658,000,000 BILLION☝6/30/2012 (3 months ended)
$65,284,000,000 BILLION☝3/31/2012 (3 months ended)
$63,674,000,000 BILLION👇.12/31/2011 (3 months ended)
$64,559,000,000 BILLION👇9/30/2011 (3 months ended)
$67,745,000,000 BILLION👇6/30/2011 (3 months ended)
$68,125,000,000 BILLION☝3/31/2011 (3 months ended)
$65,601,000,000 BILLION👇.12/31/2010 (3 months ended)
$67,384,000,000 BILLION☝9/30/2010 – (3 months ended)
$64,580,000,000 BILLION👇6/30/2010 (3 months ended)
$67,726,000,000 BILLION👇3/31/2010 (3 months ended)
$69,007,000,000 BILLION☝.12/31/2009 (3 months ended)
$66,315,000,000 BILLION☝9/30/2009 (3 months ended)
$59,336,000,000 BILLION☝6/30/2009 (3 months ended)
$56,009,000,000 BILLION☝3/31/2009 (3 months ended)
======================================

======================================
REFERENCES:
======================================
[1] – 12/2/2013 – Robert J. (don’t call me “Bobby”) “Bob” (I’m NOT a doctor, I just pretend that I’m one on The Other Burzynski Patient Group (TOBPG)) Blaskiewicz Blatherskitewicz’s Burzynski “IS big pharma”::
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/12/02/robert-j-dont-call-me-bobby-bob-im-not-a-doctor-i-just-play-like-im-one-on-the-other-burzynski-patient-group-tobpg-blaskiewicz-blatherskitewicz/
======================================
[2] – 11/26/2013 – United States Department of Justice (DOJ) versus BIG Pharma: BIG Pharma fought the law, and the law won ?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/26/united-states-department-of-justice-versus-big-pharma-big-pharma-fought-the-law-and-the-law-won/
======================================
2013

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2013/Q3-2013-US-dollar-translation.pdf
——————————————————————
2013

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2013/Q2-2013-US-dollar-translation.pdf
——————————————————————
2013

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2013/Q1-2013-US-dollar-translation.pdf
======================================
2012

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2012/Q4-2012-US-dollar-translation.pdf
——————————————————————
2012

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2012/Q3-2012-US-dollar-translation.pdf
——————————————————————
2012

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2012/Q2-2012-US-dollar-translation.pdf
——————————————————————
2012

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2012/Q1-2012-US-dollar-translation.pdf
======================================
2011

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2011/Q4-2011-US-dollar-translation.pdf
——————————————————————
2011

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2011/Q3-2011-US-dollar-translation.pdf
——————————————————————
2011

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2011/Q2-2011-US-dollar-translation.pdf
——————————————————————
2011

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2011/Q1-2011-US-dollar-translation.pdf
======================================
2010

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2010/Q4-2010-US-dollar-translation.pdf
——————————————————————
2010

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2010/Q3-2010-US-dollar-translation.pdf
——————————————————————
2010

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2010/Q2-2010-US-dollar-translation.pdf
——————————————————————
2010

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2010/Q1-2010-US-dollar-translation.pdf
======================================
2009

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2009/Q4-2009-US-dollar-translation.pdf
——————————————————————
2009

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2009/Q3-2009-US-dollar-translation.pdf
——————————————————————
2009

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2009/Q2-2009-US-dollar-translation.pdf
——————————————————————
2009

——————————————————————
http://www.gsk.com/content/dam/gsk/globals/documents/pdf/Investors/quarterly-results/2009/Q1-2009-US-dollar-translation.pdf
======================================

United States Department of Justice (DOJ) versus BIG Pharma: BIG Pharma fought the law, and the law won ?

——————————————————————
6/20/2003 – “Today’s plea and settlement demonstrates our strong commitment to protecting the American public from corporate greed, in whatever form that it may occur”

“THIS CASE SENDS A STRONG MESSAGE TO THE PHARMACEUTICAL INDUSTRY that fraudulent activity . . . will not be tolerated and will be investigated and prosecuted to the full extent of the law.”
——————————————————————
It’s now been over 10 years

NOT SO MUCH ?
——————————————————————
INSANITY: Doing the same thing over and over and expecting a different result
——————————————————————

======================================
BY DOLLAR ($) AMOUNT:
======================================

======================================
$3 BILLION ($3,000,000,000) – 2/7/2012, Monday – GlaxoSmithKline LLC (GSK) (4/1998 – 2007)
======================================

======================================
$2.3 BILLION ($2,300,000,000) – 9/2/2009, Wednesday – Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc.
======================================

======================================
$2.2 BILLION + ($2,200,000,000) – 11/4/2013, Monday – Johnson & Johnson (J&J) and subsidiaries, Janssen Pharmaceuticals Inc. and Scios Inc. (1998 – 2009)
======================================

======================================
$1.5 BILLION ($1,500,000,000) – 5/7/2012 – Abbott Laboratories (1/1998 – 12/2006)
======================================

======================================
$1.415 BILLION ($1,400,000,000) – 1/15/2009, Thursday – Eli Lilly and Company, headquartered in Indianapolis, Indiana (9/1999 – end 2005)
======================================

======================================
$950 MILLION ($950,000,000)- 11/22/2011, Tuesday – Merck Sharp & Dohme
======================================

======================================
$875 MILLION ($875,000,000) – 10/2001 – TAP Pharmaceuticals, Inc. (TAP)
======================================

======================================
$762 MILLION ($762,000,000) – .12/19/2012, Wednesday – Amgen Inc.
======================================

======================================
$650 MILLION ($650,000,000) – 2/7/2008, Thursday – Merck & Company
======================================

======================================
$520 MILLION ($520,000,000) – 4/27/2010, Tuesday – AstraZeneca LP / AstraZeneca Pharmaceuticals LP, Wilmington, Delaware-based company (1/2001 – 12/2006)
======================================

======================================
$490.9 MILLION ($490,900,000) – 7/30/2013, Tuesday – Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009 (1998 – 2009)
======================================

======================================
$425 MILLION ($425,000,000) – 9/29/2008, Monday – Cephalon Inc., Biopharmaceutical Company
======================================

======================================
$355 MILLION ($355,000,000) – 6/20/2003, Friday – AstraZeneca Pharmaceuticals LP – (1/1991 – 12/31/2002)
======================================

======================================
$345 MILLION ($345,000,000) – 7/30/2004, Friday – Schering Sales Corp., sales and marketing subsidiary of drug manufacturer Schering-Plough Corporation
======================================

======================================
$85 MILLION ($85,000,000) – 10/5/2011, Wednesday – Johnson & Johnson Subsidiary Scios Inc., Fremont, California-Based Company
======================================

======================================
$55 MILLION + interest ($55,000,000) – 12/12/2012, Wednesday – Wyeth LLC / Pfizer
======================================

======================================
$48.26 MILLION ($48,260,000) – 5/13/2013, Monday – C.R. Bard Inc., New Jersey based corporation
======================================

======================================
$36 MILLION ($36,000,000) – 11/21/2005, Wednesday – Eli Lilly and Company, Indianapolis, Indiana-based company
======================================

======================================

======================================
BY DATE:
======================================

======================================
11/4/2013, Monday – $2.2 BILLION + – Johnson & Johnson (J&J) and subsidiaries, Janssen Pharmaceuticals Inc. and Scios Inc. (1998 – 2009)
======================================

======================================
7/30/2013, Tuesday – $490.9 MILLION – Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009 (1998 – 2009)
======================================

======================================
5/13/2013, Monday – $48.26 MILLION – C.R. Bard Inc., New Jersey based corporation
======================================

======================================
12/19/2012, Wednesday – $762 MILLION – Amgen Inc.
======================================

======================================
12/12/2012, Wednesday – $55 MILLION + interest – Wyeth LLC / Pfizer
======================================

======================================
5/7/2012 – $1.5 BILLION – Abbott Laboratories (1/1998 – 12/2006)
======================================

======================================
2/7/2012, Monday – $3 BILLION – GlaxoSmithKline LLC (GSK) (4/1998 – 2007)
======================================

======================================
11/22/2011, Tuesday – $950 MILLION – Merck Sharp & Dohme
======================================

======================================
10/5/2011, Wednesday – $85 MILLION – Johnson & Johnson Subsidiary Scios Inc., Fremont, California-Based Company
======================================

======================================
4/27/2010, Tuesday – $520 MILLION – AstraZeneca LP / AstraZeneca Pharmaceuticals LP, Wilmington, Deleware-based company (1/2001 – 12/2006)
======================================

======================================
9/2/2009, Wednesday – $2.3 BILLION – Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc.
======================================

======================================
1/15/2009, Thursday – $1.415 BILLION – Eli Lilly and Company, headquartered in Indianapolis, Indiana (9/1999 – end 2005)
======================================

======================================
9/29/2008, Monday – $425 MILLION ($425,000,000) – Cephalon Inc., Biopharmaceutical Company
======================================

======================================
2/7/2008, Thursday – $650 MILLION – Merck & Company
======================================

======================================
11/21/2005, Wednesday – $36 MILLION – Eli Lilly and Company, Indianapolis, Indiana-based company
======================================

======================================
7/30/2004, Friday – $345 MILLION – Schering Sales Corp., sales and marketing subsidiary of drug manufacturer Schering-Plough Corporation
======================================

======================================
6/20/2003, Friday – $355 MILLION ($355,000,000) – AstraZeneca Pharmaceuticals LP – (1/1991 – 12/31/2002)
======================================

======================================
10/3/2001 – $875 MILLION – TAP Pharmaceuticals, Inc. (TAP)
======================================

======================================

======================================
ALPHABETICALLY:
======================================

======================================
Abbott Laboratories: 5/7/2012 – (1/1998 – 12/2006)
======================================
$1.5 BILLION
CIVIL LIABILITY
CRIMINAL LIABILITY
——————————————————————
$800 million – civil settlements
——————————————————————
$560,851,357 million – federal government
——————————————————————
$239,148,643 million – the States
——————————————————————
$700 million – criminal fine and forfeiture
——————————————————————
$500 million – criminal fine
——————————————————————
$198.5 million – forfeit assets
——————————————————————
$1.5 million – Virginia Medicaid Fraud Control Unit
——————————————————————
($84 million – whistleblowers will receive from federal share of settlement amount)
======================================

======================================
Amgen Inc. – 12/19/2012, Wednesday – Amerisourcebergen Corporation Subsidiary International Nephrology Network
======================================
$762 MILLION ($762,000,000) – Amgen criminal and civil liability part of global settlement with United States
——————————————————————
$612 million – Amgen agreed to pay As part of civil settlement
——————————————————————
$587.2 million – United States
——————————————————————
$24.8 million – the states
——————————————————————
$150 Million – Criminal Penalties and Forfeiture
——————————————————————
$136 million – Amgen criminal fine
——————————————————————
$14 million – Amgen criminal forfeiture
——————————————————————
$15 Million – Amerisourcebergen Corporation Subsidiary International Nephrology Network Resolve Qui Tam Action
======================================

======================================
AstraZeneca LP / AstraZeneca Pharmaceuticals LP, Wilmington, Delaware-based company 4/27/2010, Tuesday – (1/2001 – 12/2006)
======================================
$520 MILLION
——————————————————————
$301,907,007 million – federal government
——————————————————————
$218,092,993 million – State Medicaid programs and District of Columbia will share up to
——————————————————————
$45 million + – James Wetta, whistleblower will receive from federal share of civil recovery
======================================

======================================
AstraZeneca Pharmaceuticals LP – 6/20/2003, Friday – (1/1991 – 12/31/2002)
======================================
$355 MILLION
$355,000,000
CRIMINAL CHARGES
CIVIL LIABILITIES
——————————————————————
$266,127,844 million – federal civil liabilities
——————————————————————
$24,900,000 million – civil liabilities United States and the States
——————————————————————
$63,872,156 million – criminal fine
——————————————————————
($39,920,098 million – losses to federally funded insurance programs)
——————————————————————
10/2001 – $875,000,000 million – TAP Pharmaceuticals, Inc. (TAP)
civil liabilities
criminal liabilities
——————————————————————
$47.5 million – Douglas Durand was employed as Vice President of Sales for TAP Pharmaceutical Products, Inc. will receive 17% share of civil recovery
======================================

======================================
C.R. Bard Inc., New Jersey based corporation – 5/13/2013, Monday –
======================================
$48.26 million
——————————————————————
$2.2 million – non-prosecution agreement
——————————————————————
$10,134,600 – Civil settlement resolves lawsuit filed by Julie Darity, former manager for brachytherapy contracts administration under qui tam, whistleblower provisions, of False Claims Act, will receive as share of civil settlement
======================================

======================================
Cephalon Inc., Biopharmaceutical Company – 9/29/2008, Monday
======================================
$425 MILLION
($425,000,000)
——————————————————————
$375 million + interest – separate civil settlement executed contemporaneously with guilty plea agreement, to resolve False Claims Act allegations arising from claims to:
1. Medicaid
2. Medicare
3. other federal programs
including:
a. Bureau of Prisons
b. Defense Logistics Agency
c. Every Employees Occupational Illness Compensation Program
d. Federal Employees Compensation Act Program
e. Federal Employees Health Benefits program
f. Postal Worker’s Compensation Program
g. Public Health Service Entities
h. TRICARE
i. Department of Veterans Affairs
——————————————————————
$116 million – State Medicaid programs will share civil settlement:
California
Delaware
Florida
Hawaii
Illinois
Louisiana
Massachusetts
Nevada
New Hampshire
New Mexico
Texas
Tennessee
Virginia
District of Columbia
——————————————————————
$50 million – In plea agreement with United States, agreed to pay to resolve Information
——————————————————————
$40 million – applied to criminal fine
——————————————————————
$10 million – applied as substitute assets to satisfy forfeiture obligation
——————————————————————
$46,469,978 MILLION – Relator Paccione will receive from federal share of settlement amount, proceeds will be shared by plaintiffs under separate agreement
======================================

======================================
Eli Lilly and Company, headquartered in Indianapolis, Indiana 1/15/2009, Thursday –
(9/1999 – end 2005)
======================================
$1.415 BILLION
CRIMINAL SETTLEMENT
CIVIL SETTLEMENT
——————————————————————
$800 million (up to) – federal government and States civil settlement agreement
——————————————————————
$438,171,544 million – federal government civil settlement
——————————————————————
$361,828,456 million (share up to) – States Medicaid programs that opt to participate in civil settlement agreement and District of Columbia
——————————————————————
$515 million – criminal fine
——————————————————————
$100 million – forfeit assets
——————————————————————
($78,870,877 million – qui tam relators from federal share of settlement amount)
——————————————————————
10/7/2008 – $62 million – 33 state consumer protection lawsuits settlements
======================================

======================================
Eli Lilly and Company, Indianapolis, Indiana-based company 11/21/2005, Wednesday
======================================
$36 million
——————————————————————
$24 million – civil liabilities
——————————————————————
$6 million – criminal fine
——————————————————————
$6 million – forfeit
======================================

======================================
GlaxoSmithKline LLC (GSK) 2/7/2012, Monday – (4/1998-2007)
======================================
$3 BILLION
criminal liability
civil liability
——————————————————————
$2 BILLION – federal government civil liabilities
——————————————————————
$1.043 BILLION – false claims arising from alleged conduct
——————————————————————
$832 million – federal share of settlement
——————————————————————
$210 million – States share of settlement
——————————————————————
$1 BILLION
——————————————————————
$956,814,400 million – criminal fine
——————————————————————
$43,185,600 million – forfeiture
——————————————————————
$757,387,200 million – criminal fine and forfeiture (2 drugs)
——————————————————————
$242,612,800 million – criminal fine (1 drug)
——————————————————————
$657 million – false claims arising from misrepresentations (1 drug)
——————————————————————
$508 million – federal share of settlement
——————————————————————
$149 million – States share of settlement
——————————————————————
$300 million – to resolve allegations
——————————————————————
$160,972,069 million – federal government
——————————————————————
$118,792,931 million – States
——————————————————————
$20,235,000 million – certain Public Health Service entities
======================================

======================================
Johnson & Johnson (J&J) and subsidiaries, Janssen Pharmaceuticals Inc. and Scios Inc. 11/4/2013, Monday – (1998 – 2009)
======================================
$2.2 BILLION +
CRIMINAL LIABILITY
CIVIL LIABILITY
——————————————————————
$1.72 billion – civil settlements with federal government and States
——————————————————————
$485 million – criminal fines and forfeiture
——————————————————————
$400 million
——————————————————————
$334 million – criminal fine
——————————————————————
$66 million – forfeiture
——————————————————————
$1.391 billion – false claims allegedly resulting from off-label marketing and kickbacks for 2 drugs includes
——————————————————————
$1.273 billion – resolution
——————————————————————
$118 million – paid to state of Texas 3/2012 to resolve similar allegations relating to 1 drug
——————————————————————
additional payment as part of settlement shared between federal and state governments
——————————————————————
$749 million – federal government recovering
——————————————————————
$524 million – the States recovering
——————————————————————
$59 million – federal government and Texas each received from Texas settlement
——————————————————————
$149 million – kickback allegations settlement
——————————————————————
$132 million – federal share of settlement
——————————————————————
$17 million – 5 participating states’ total share of settlement
——————————————————————
$98 million – 2009 – Omnicare civil liability
——————————————————————
J&J and its subsidiary, Scios Inc.
——————————————————————
$184 million – federal government civil liability
——————————————————————
$85 million – 10/2011 criminal fine
——————————————————————
From federal government’s share of civil settlements
——————————————————————
$112 million – whistleblowers in Eastern District of Pennsylvania
——————————————————————
$27.7 million – whistleblowers in District of Massachusetts
——————————————————————
$28 million – whistleblower in Northern District of California
======================================

======================================
Johnson & Johnson Subsidiary Scios Inc., Fremont, California-Based Company 10/5/2011, Wednesday
======================================
$85 million – criminal fine
======================================

======================================
Merck Sharp & Dohme 11/22/2011, Tuesday – (1999 – 2002)
======================================
$950 MILLION
CIVIL CLAIMS
CRIMINAL CHARGES
——————————————————————
$628,364,000 million – civil settlement agreement
——————————————————————
$426,389,000 million – United States civil settlement
——————————————————————
$321,636,000 million – criminal fine
——————————————————————
$201,975,000 million – Medicaid states civil settlement
======================================

======================================
Merck & Company 2/7/2008, Thursday
======================================
$650 MILLION – 2 cases
——————————————————————
$399 million + interest
——————————————————————
$250 million + interest
——————————————————————
$360 million + – federal government settlement agreement
——————————————————————
$290 million + – 49 states and District of Columbia settlement agreements
——————————————————————
$44,690,000 million – Mr. H. Dean Steinke, former Merck employee from federal share of settlement amount (1997 – 2001)
——————————————————————
$23.5 million – Mr. H. Dean Steinke, former Merck employee from the states share of settlement amount (1997 – 2001)
——————————————————————
Dr. William St. John LaCorte in New Orleans will receive share of proceeds from federal and state settlement amounts under their respective qui tam statutes
======================================

======================================
Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. 9/2/2009, Wednesday
======================================
$2.3 BILLION
CIVIL LIABILITY
CRIMINAL LIABILITY
——————————————————————
$1.3 billion – total criminal resolution
——————————————————————
$1.195 billion – criminal fine
——————————————————————
$1 billion – civil
——————————————————————
$668,514,830 million – federal share of civil settlement
——————————————————————
$331,485,170 million – state Medicaid share of civil settlement
——————————————————————
$105 million – Pharmacia & Upjohn forfeit
——————————————————————
$102 million + – 6 whistleblowers will receive payments from federal share of civil recovery
======================================

======================================
Wyeth LLC Pfizer
======================================
12/12/2012, Wednesday
======================================
$55 MILLION + interest
======================================

======================================
Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009 7/30/2013, Tuesday – (1998 – 2009)
======================================
$490.9 MILLION
CIVIL LIABILITY
CRIMINAL LIABILITY
——————————————————————
$257.4 million – civil settlements with federal government and states
——————————————————————
$233.5 million – criminal fine and forfeiture
——————————————————————
$230,112,596 million – federal government civil claims
——————————————————————
$157.58 million – criminal fine
——————————————————————
$76 million – forfeit assets
——————————————————————
$27,287,404 million – States civil claims
——————————————————————
whistleblowers’ share of civil settlement hasn’t been resolved
——————————————————————
1st action – filed by former Rapamune sales representative, Marlene Sandler, and pharmacist, Scott Paris
——————————————————————
2nd action – filed by former Rapamune sales representative, Mark Campbell
======================================

======================================
Schering Sales Corp., sales and marketing subsidiary of drug manufacturer Schering-Plough Corporation 7/30/2004, Friday
======================================
$345 MILLION
——————————————————————
$292,969,482 million – United States, 50 state Medicaid programs, certain Public Health Service entities
——————————————————————
$290 million + – Schering-Plough Corporation civil liabilities
——————————————————————
$52.5 million – Schering Sales Corp. criminal charges fine
——————————————————————
$31,662,173 million – Charles Alcorn, Beatrice Manning, and Raymond Pironti, Jr., (“the relators”) 3 former employees of ITG, Inc. a subsidiary of Schering Plough – civil resolution
======================================

======================================

======================================
REFERENCES:
======================================
5/7/2012, Monday – Abbott Laboratories
——————————————————————
http://www.justice.gov/opa/pr/2012/May/12-civ-585.html
======================================
5/7/2012, Monday – Abbott Laboratories
——————————————————————
http://www.justice.gov/opa/abbott-labs-docs.html
======================================
10/2/2012, Tuesday – Abbott Laboratories
——————————————————————
http://www.justice.gov/opa/pr/2012/October/12-civ-1195.html
======================================
12/19/2012, Wednesday – Amgen Inc.
——————————————————————
http://www.justice.gov/opa/pr/2012/December/12-civ-1523.html
======================================
4/27/2010, Tuesday – AstraZeneca Pharmaceuticals LP
——————————————————————
http://www.justice.gov/opa/pr/2010/April/10-civ-487.html
======================================
4/27/2010, Tuesday – AstraZeneca Pharmaceuticals LP
——————————————————————
http://www.justice.gov/usao/pae/Pharma-Device/astrazeneca_settlementagreement.pdf
======================================
6/20/2003, Friday – AstraZeneca Pharmaceuticals LP
——————————————————————
http://www.justice.gov/opa/pr/2003/June/03_civ_371.html
======================================
5/13/2013, Monday – C.R. Bard Inc., New Jersey based corporation
——————————————————————
http://www.justice.gov/opa/pr/2013/May/13-civ-547.html
======================================
9/29/2008, Monday – Cephalon Inc., Biopharmaceutical Company
——————————————————————
http://www.justice.gov/opa/pr/2008/September/08-civ-860.html
======================================
1/15/2009, Thursday – Eli Lilly and Company
——————————————————————
http://www.justice.gov/opa/pr/2009/January/09-civ-038.html
======================================
12/21/2005, Wednesday – Eli Lilly and Company
——————————————————————
http://www.justice.gov/opa/pr/2005/December/05_civ_685.html
======================================
7/2/2012, Monday – GlaxoSmithKline LLC (GSK)
——————————————————————
http://www.justice.gov/opa/pr/2012/July/12-civ-842.html
======================================
11/4/2013, Monday – Johnson & Johnson (J&J) and subsidiaries
——————————————————————
http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html
======================================
10/5/2011, Wednesday – Johnson & Johnson (J&J) Subsidiary Scios Inc.
——————————————————————
http://www.justice.gov/opa/pr/2011/October/11-civ-1323.html
======================================
11/22/2011, Tuesday – Merck Sharp & Dohme
——————————————————————
http://www.justice.gov/opa/pr/2011/November/11-civ-1524.html
======================================
2/7/2008, Thursday – Merck & Company
——————————————————————
http://www.justice.gov/opa/pr/2008/February/08_civ_094.html
======================================
9/2/2009, Wednesday – Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc.
——————————————————————
http://www.justice.gov/opa/pr/2009/September/09-civ-900.html
======================================
12/12/2012, Wednesday – Wyeth LLC Pfizer
——————————————————————
http://www.justice.gov/opa/pr/2012/December/12-civ-1488.html
======================================
7/30/2013, Tuesday – Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009
——————————————————————
http://www.justice.gov/opa/pr/2013/July/13-civ-860.html
======================================
7/30/2004, Friday – Schering Sales Corp., sales and marketing subsidiary of drug manufacturer Schering-Plough Corporation
——————————————————————
http://www.justice.gov/opa/pr/2004/July/04_civ_523.htm
======================================
10/3/2001, Wednesday – TAP Pharmaceutical Products Inc. (TAP)
——————————————————————
http://www.justice.gov/opa/pr/2001/October/513civ.htm
======================================